Post-Treatment PSA Level May Predict RT Outcomes
|
By MedImaging International staff writers Posted on 14 Jun 2018 |
|
Prostate-specific antigen (PSA) levels three months after radiotherapy (RT) are strong markers of prostate cancer outcomes, according to a new study.
Researchers at the University of California, San Diego (UCSD, USA) and Dana-Farber Cancer Institute (Boston, MA, USA) conducted a study involving 5,783 patients with intermediate-risk or high-risk localized prostate cancer diagnosed in the years 2000-2015 and treated with RT and androgen deprivation therapy. The aim of the study was to examine the association between three-month post-RT PSA level and biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS), and overall survival (OS).
In all, there were 2,651 patients with intermediate-risk and 3,132 with high-risk disease, with about 11% harboring a three-month PSA level higher than 0.50 ng/mL, which was found to be strongly associated with each outcome, as compared to patients with a three-month PSA value lower than 0.10 ng/mL. When the groups were analyzed separately, three-month PSA level was found to be predictive of OS in the high-risk group, but not in the intermediate-risk group. The study was published on May 4, 2018, in Cancer.
“The three month post‐RT PSA level appears to be a strong prognostic biomarker for bPFS, PCSS, and OS in patients with intermediate‐risk and high‐risk prostate cancer, particularly those with high‐risk disease,” concluded lead author Alex Bryant, BSc, of the UCSD department of radiation medicine and applied sciences, and colleagues. “The three month PSA measurement may augment clinical decision making and holds promise as a potential surrogate endpoint in clinical trials.”
PSA is a glycoprotein enzyme secreted by the epithelial cells of the prostate gland, and is encoded in humans by the kallikrein-3 (KLK3) gene. PSA is produced for the ejaculate, where it liquefies semen in the seminal coagulum, allowing sperm to swim freely; it is also believed to be involved in dissolving cervical mucus, allowing the entry of sperm into the uterus. PSA is present in small quantities in the serum of men with healthy prostates, but is elevated in the presence of prostate cancer, prostatitis or benign prostatic hyperplasia (BPH).
Related Links:
University of California, San Diego
Dana-Farber Cancer Institute
Researchers at the University of California, San Diego (UCSD, USA) and Dana-Farber Cancer Institute (Boston, MA, USA) conducted a study involving 5,783 patients with intermediate-risk or high-risk localized prostate cancer diagnosed in the years 2000-2015 and treated with RT and androgen deprivation therapy. The aim of the study was to examine the association between three-month post-RT PSA level and biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS), and overall survival (OS).
In all, there were 2,651 patients with intermediate-risk and 3,132 with high-risk disease, with about 11% harboring a three-month PSA level higher than 0.50 ng/mL, which was found to be strongly associated with each outcome, as compared to patients with a three-month PSA value lower than 0.10 ng/mL. When the groups were analyzed separately, three-month PSA level was found to be predictive of OS in the high-risk group, but not in the intermediate-risk group. The study was published on May 4, 2018, in Cancer.
“The three month post‐RT PSA level appears to be a strong prognostic biomarker for bPFS, PCSS, and OS in patients with intermediate‐risk and high‐risk prostate cancer, particularly those with high‐risk disease,” concluded lead author Alex Bryant, BSc, of the UCSD department of radiation medicine and applied sciences, and colleagues. “The three month PSA measurement may augment clinical decision making and holds promise as a potential surrogate endpoint in clinical trials.”
PSA is a glycoprotein enzyme secreted by the epithelial cells of the prostate gland, and is encoded in humans by the kallikrein-3 (KLK3) gene. PSA is produced for the ejaculate, where it liquefies semen in the seminal coagulum, allowing sperm to swim freely; it is also believed to be involved in dissolving cervical mucus, allowing the entry of sperm into the uterus. PSA is present in small quantities in the serum of men with healthy prostates, but is elevated in the presence of prostate cancer, prostatitis or benign prostatic hyperplasia (BPH).
Related Links:
University of California, San Diego
Dana-Farber Cancer Institute
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Brachytherapy Planning System
Oncentra Brachy
New
Wireless Handheld Ultrasound System
TE Air
Color Doppler Ultrasound System
DRE Crystal 4PX
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
Channels
Radiography
view channel
Novel Breast Imaging System Proves As Effective As Mammography
Breast cancer remains the most frequently diagnosed cancer among women. It is projected that one in eight women will be diagnosed with breast cancer during her lifetime, and one in 42 women who turn 50... Read more
AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
Radiologists typically detect one case of cancer for every 200 mammograms reviewed. However, these evaluations often result in false positives, leading to unnecessary patient recalls for additional testing,... Read more
MRI
view channel
Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
Magnetic Resonance Imaging (MRI) has significantly transformed healthcare, providing a noninvasive, radiation-free method for detailed imaging. It is especially promising for the future of medical diagnosis... Read more
World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
The world's first whole-body ultra-high field (UHF) MRI has officially come to market, marking a remarkable advancement in diagnostic radiology. United Imaging (Shanghai, China) has secured clearance from the U.... Read more
Ultrasound
view channel.jpg "Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)")
Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease
Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more
Super-Resolution Imaging Technique Could Improve Evaluation of Cardiac Conditions
The heart depends on efficient blood circulation to pump blood throughout the body, delivering oxygen to tissues and removing carbon dioxide and waste. Yet, when heart vessels are damaged, it can disrupt... Read more
First AI-Powered POC Ultrasound Diagnostic Solution Helps Prioritize Cases Based On Severity
Ultrasound scans are essential for identifying and diagnosing various medical conditions, but often, patients must wait weeks or months for results due to a shortage of qualified medical professionals... Read more
General/Advanced Imaging
view channel
Bone Density Test Uses Existing CT Images to Predict Fractures
Osteoporotic fractures are not only devastating and deadly, especially hip fractures, but also impose significant costs. They rank among the top chronic diseases in terms of disability-adjusted life years... Read more
AI Predicts Cardiac Risk and Mortality from Routine Chest CT Scans
Heart disease remains the leading cause of death and is largely preventable, yet many individuals are unaware of their risk until it becomes severe. Early detection through screening can reveal heart issues,... Read more
Imaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Hologic, Inc. (Marlborough, MA, USA) has entered into a definitive agreement to acquire Endomagnetics Ltd. (Cambridge, UK), a privately held developer of breast cancer surgery technologies, for approximately... Read more
Bayer and Google Partner on New AI Product for Radiologists
Medical imaging data comprises around 90% of all healthcare data, and it is a highly complex and rich clinical data modality and serves as a vital tool for diagnosing patients. Each year, billions of medical... Read more
